Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Cannabis benefits mount up for Cambridge science
Published: 16:34, 27 June 2019
With cannabis now legally available in the UK for medical use, applications are being investigated, so it is timely that Cambridge is hosting a two-part conference on the topic.
The two-part pilot, at The Old Divinity School – on July 7 and August 4 – will see the topic of medical cannabis discussed for the first time in Cambridge.
Organised by CANNTalks – ‘Curating A New Normal’ refers directly to the changes in cannabis reform happening globally – the events are titled ‘Live Talks: A Conversation on Cannabis’. The founders are a collective of scientists, academics, artists, activist disruptors, and influencers.
They describe the occasion as “a deep-dive into the science of the deepest parts of the plant-human relationship, illuminating on the complexities of the plant herself, before moving towards the regulatory changes; as well as exploring the philosophy and the ethics that have been behind prohibition for the last 90 years”.
One of those attending will be Dan Gooding, CEO of Nuformix, the Science Park-based pharmaceutical development company which uses cocrystal technology to unlock therapeutic potential of approved drugs in oncology supportive care and fibrosis.
“The event in Cambridge is very international,” Dan says. “It’s bringing together academics, patients, parents of patients – such as children with epilepsy – and regulators, and there’s a comprehensive list of topics about what’s going on and giving it airtime. We’ll be there!”
There is a heightened interest because Nuformix recently signed an agreement with Canadian firm Ebers Tech Inc. Ebers is “backed by leaders from the financial sector focused on the development of superior, differentiated cannabinoid products for a multitude of consumer product and therapeutic applications”.
The agreement – which saw Nuformix’s share price jump 30 per cent – is for the development, licensing and commercialisation of cannabinoid therapeutics and involves “up to £51million of upfront R&D and milestone payments, plus long-term royalties of 20 per cent of net sales medical cannabis”. It includes an upfront payment, with early-stage milestone payments expected this year.
So what’s the fuss about? Well, cannabis is entirely legal in Canada so there’s a healthy market to work with. The market in the US has also opened up to medical cannabis and that’s created interest in the UK.
GW Pharmaceuticals in Histon is already a global leader in developing cannabinoid-based medicines.
First off the block is cannabidiol, or CBD, which is an active ingredient in cannabis derived from the hemp plant – and it should be pointed out that this form of medical cannabis has zero THC, or tetrahydrocannabinol, which is the ingredient that gives “weed” its psychoactive effects.
continues....
https://www.cambridgeindependent.co.uk/news/cannabis-benefits-mount-up-for-cambridge-science-9074755/
China biotech groups spend billions on overseas drug candidates
US and European pharma groups benefit from cash-rich Chinese sector seeking new medicines
link to full article
https://www.ft.com/content/869a918c-9185-11e9-aea1-2b1d33ac3271
Big companies are scrambling to grab a share of the $150bn (£119bn) global cannabis market, eyeing products as diverse as beer and dog treats.
That's according to a report by Standard & Poor's which predicts further expansion as legal cannabis becomes acceptable.
The report by the ratings agency says growth may be volatile, because of the changing regulatory framework.
But it points to growth in sectors such as healthcare, alcoholic beverages, soft drinks, tobacco, beauty and healthcare.
Indeed, two of the biggest investments in the sector have come from Altria, owner of Philip Morris cigarettes, and Constellation Brands, owner of Corona beer, which have each invested more than $1bn in such products.
continues
https://www.bbc.co.uk/news/business-48718588
23rd - 29th June 2019
A FIRST FOR EUROPE
A FIRST FOR LONDON
A FIRST FOR CANNABIS
ECW showcases the people and companies shaping the European cannabis industry with an inspiring programme of talks, networking and cultural events.
https://www.ecwevents.com/
For newbies, well worth listening to interview of Dan Gooding on May 15th after recent NXP001 announcement.
https://audioboom.com/posts/7261689-nuformix-achieve-development-milestone-toople-on-their-interims-and-john-meyer-on-resource-stocks
One telling quote of many in interview is @ 9mins 30ses
"I'm out here working with our partner now, actually looking at our routes to market and how we can make sure that that happens as fast as possible''
First dosing of NXP001 took place successfully on 20 March 2019 in a cross-over study that aims to measure the relative bioavailability of NXP001 compared to Merck's EMEND® in healthy subjects. Dosing will complete during April 2019 with results expected by end H1 2019.
Worth noting that sales of Merck's EMEND totaled $556m in Merck's 2017 results
https://investors.merck.com/news/press-release-details/2018/Merck-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results/default.aspx
@ 9 mins 30 secs of the Vox Markets interview today , Dan Gooding said
"I'm out here working with our partner now, actually looking at our routes to market and how we can make sure that that happens as fast as possible"
IMO this sounds like the statement from someone very confident that the results of the trial will be positive.
Reports Results from Novel IPF Pre-Clinical Trial
RNS Number : 1394J
Nuformix PLC
03 December 2018
NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)
For info:
FDA approved Esbriet for treatment of idiopathic pulmonary fibrosis in 2014. The drug, whose revenue stood at $48 million in 2014, garnered nearly $856 million in 2017
First dosing of NXP001 took place successfully on 20 March 2019 in a cross-over study that aims to measure the relative bioavailability of NXP001 compared to Merck's EMEND® in healthy subjects. Dosing will complete during April 2019 with results expected by end H1 2019.
Worth noting that sales of Merck's EMEND totaled $556m in Merck's 2017 results
https://investors.merck.com/news/press-release-details/2018/Merck-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results/default.aspx
For info
Commenting on the Disposal, CEO Lorne Abony noted, "The partial sale of the Company's interest in Vemo is the Company's first exit from an investment in 2019. The Board believes further investments can be realized during the course of 2019 and intends to reinvest the proceeds in the medicinal cannabis sector, furthering FFWDs investment focus on life science, health and technology."
The CEO statement at the end of the RNS issued on the 9th April wrt Strategic Cannabinoid Agreement, he certainly seems to be confident in the outcome of the NPX001 trial.
"Given the progress made with our NXP001 programme, we have proven our capability to develop products with a short path to market that utilise our IP and technology.
The agreement allows Nuformix and its shareholders to benefit immediately from the upside of this attractive market without exposure to development and commercialisation risk. We are able to focus on developing our clinical and early-stage portfolios as planned, whilst generating significant near term revenue via attractive development milestones and a strong royalty component. We look forward to sharing further details with the market as the partnership progresses."
Another director buy today just RNSed.